Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

SCH 51344, an inhibitor of RAS/RAC-mediated cell morphology pathway.

C C Kumar1, K Ohashi, K Nagata

  • 1Department of Tumor Biology, Schering-Plough Research Institute, Kenilworth, New Jersey 07033, USA. Chandra.kumar@spcorp.com

Annals of the New York Academy of Sciences
|February 10, 2000
PubMed
Summary

SCH 51344 inhibits RAS transformation by blocking membrane ruffling, a key pathway distinct from ERK signaling. This compound offers a novel mechanism for targeting oncogene-induced cell transformation.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparison of bacterial contamination between disposable and cloth caps in an operating theatre setting.

Infection prevention in practice·2025
Same author

Social Deprivation among Children with Inherited Metabolic Disorders.

Irish medical journal·2025
Same author

Opportunistic Measles Immunisation within the Paediatric Inclusion Health Service.

Irish medical journal·2025
Same author

A case report of Penicillium chorioretinitis in a Border Collie dog.

Australian veterinary journal·2024
Same author

Meteorological gaps in audits of pedestrian environments: a scoping review.

BMC public health·2024
Same author

Impact and process evaluation of a primary-school Food Education and Sustainability Training (FEAST) program in 10-12-year-old children in Australia: pragmatic cluster non-randomized controlled trial.

BMC public health·2024

Area of Science:

  • Cell Biology
  • Molecular Oncology
  • Signal Transduction

Background:

  • RAS proteins are key regulators of cell signaling pathways, including ERK activation and membrane ruffling, which synergistically drive cell transformation.
  • The human smooth muscle alpha-actin promoter serves as a sensitive marker for phenotypic changes in RAS-transformed fibroblasts.
  • SCH 51344, a pyrazoloquinoline derivative, was identified for its ability to derepress the alpha-actin promoter in RAS-transformed cells.

Purpose of the Study:

  • To investigate the mechanism of action of SCH 51344, a potent inhibitor of RAS transformation.
  • To determine if SCH 51344 targets the ERK pathway or another mechanism in RAS-mediated transformation.
  • To evaluate SCH 51344's efficacy in inhibiting anchorage-independent growth of oncogene-transformed cells.

Main Methods:

Related Experiment Videos

  • Assessing the effect of SCH 51344 on ERK and JUN kinase activities in RAS-transformed cells.
  • Analyzing SCH 51344's impact on membrane ruffling induced by activated RAS and RAC.
  • Evaluating SCH 51344's inhibition of anchorage-independent growth in Rat-2 fibroblast cells transformed by oncogenic RAS and RAC V12.

Main Results:

  • SCH 51344 demonstrated minimal impact on ERK and JUN kinase pathway activities.
  • SCH 51344 specifically inhibited membrane ruffling induced by activated H-RAS, K-RAS, N-RAS, and RAC.
  • SCH 51344 effectively inhibited the anchorage-independent growth of fibroblast cells transformed by oncogenic RAS and RAC V12.

Conclusions:

  • SCH 51344 inhibits RAS transformation through a novel mechanism targeting the membrane ruffling pathway, downstream of RAC.
  • The membrane ruffling pathway represents a critical component in RAS-mediated cell transformation.
  • Targeting the membrane ruffling pathway offers a promising therapeutic strategy for inhibiting transformation driven by RAS and other oncogenes.